Aurélie Lagrange

1.4k total citations
22 papers, 387 citations indexed

About

Aurélie Lagrange is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Aurélie Lagrange has authored 22 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Aurélie Lagrange's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (5 papers). Aurélie Lagrange is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (5 papers). Aurélie Lagrange collaborates with scholars based in France, United States and Italy. Aurélie Lagrange's co-authors include Laure Favier, François Ghiringhelli, Bruno Coudert, Corentin Richard, Emeric Limagne, Caroline Truntzer, Jean-David Fumet, Romain Boidot, Marion Thibaudin and Courèche Kaderbhaï and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Aurélie Lagrange

19 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aurélie Lagrange France 9 267 157 103 99 46 22 387
Jean David Fumet France 7 347 1.3× 140 0.9× 87 0.8× 85 0.9× 31 0.7× 14 409
Yinan Dong China 7 190 0.7× 131 0.8× 95 0.9× 54 0.5× 35 0.8× 12 324
Rahima Jamal Canada 10 303 1.1× 106 0.7× 184 1.8× 79 0.8× 24 0.5× 33 408
Jichang Han China 6 167 0.6× 178 1.1× 60 0.6× 37 0.4× 24 0.5× 13 299
Andrea Castro United States 7 184 0.7× 133 0.8× 75 0.7× 50 0.5× 56 1.2× 14 265
Marco La Placa Italy 6 244 0.9× 212 1.4× 65 0.6× 38 0.4× 20 0.4× 9 344
François Audhuy United States 6 204 0.8× 82 0.5× 93 0.9× 61 0.6× 32 0.7× 8 310
Vanesa de Luque Spain 3 255 1.0× 158 1.0× 69 0.7× 38 0.4× 25 0.5× 3 336
Farid Ghorbaninezhad Iran 10 140 0.5× 157 1.0× 126 1.2× 40 0.4× 61 1.3× 26 333
Mei Cao China 8 160 0.6× 122 0.8× 89 0.9× 71 0.7× 85 1.8× 15 321

Countries citing papers authored by Aurélie Lagrange

Since Specialization
Citations

This map shows the geographic impact of Aurélie Lagrange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Lagrange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Lagrange more than expected).

Fields of papers citing papers by Aurélie Lagrange

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Lagrange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Lagrange. The network helps show where Aurélie Lagrange may publish in the future.

Co-authorship network of co-authors of Aurélie Lagrange

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Lagrange. A scholar is included among the top collaborators of Aurélie Lagrange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Lagrange. Aurélie Lagrange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gobbini, Élisa, Alexandra Langlais, Pascale Missy, et al.. (2025). Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. European Journal of Cancer. 225. 115560–115560.
2.
Favier, Laure, Aurélie Lagrange, Courèche Kaderbhaï, et al.. (2023). Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. International Journal of Molecular Sciences. 24(8). 7592–7592. 2 indexed citations
3.
Boidot, Romain, Philippe Bonniaud, Pascal Foucher, et al.. (2022). Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort. Journal of Thoracic Disease. 14(6). 2034–2044. 4 indexed citations
4.
Favier, Laure, Aurélie Lagrange, Courèche Kaderbhaï, et al.. (2022). MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 10(3). e004241–e004241. 12 indexed citations
5.
Truntzer, Caroline, Sandy Chevrier, Laure Favier, et al.. (2021). Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. Lung Cancer. 161. 98–107.
6.
Galland, Loïck, Laure Favier, Aurélie Lagrange, et al.. (2021). Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. Cancers. 13(12). 3020–3020. 13 indexed citations
7.
Coudert, Bruno, Aurélie Bertaut, Laure Favier, et al.. (2020). Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer. Cancer/Radiothérapie. 24(4). 279–287. 5 indexed citations
8.
Lagrange, Aurélie, et al.. (2019). Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 241. 49–55. 11 indexed citations
9.
Limagne, Emeric, Corentin Richard, Marion Thibaudin, et al.. (2019). Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. OncoImmunology. 8(4). e1564505–e1564505. 147 indexed citations
10.
11.
Gregori, Johannes, Bruno Coudert, Isabelle Desmoulins, et al.. (2019). ADHERENCE TO ORAL ANTICANCER THERAPIES IN A CLINICAL CANCER CENTRE. Journal of Geriatric Oncology. 10(6). S86–S86. 1 indexed citations
12.
Richard, Corentin, Jean-David Fumet, Sandy Chevrier, et al.. (2018). Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clinical Cancer Research. 25(3). 957–966. 38 indexed citations
13.
Richard, Corentin, Jean-David Fumet, Sandy Chevrier, et al.. (2018). Exome analysis to reveal genomic markers associated with better efficacy of nivolumab in lung cancer patients.. Journal of Clinical Oncology. 36(15_suppl). 9044–9044. 2 indexed citations
14.
Fumet, Jean-David, Corentin Richard, Quentin Klopfenstein, et al.. (2018). CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.. Journal of Clinical Oncology. 36(15_suppl). 3021–3021.
15.
Richard, Corentin, Jean David Fumet, Sandra Ortiz‐Cuaran, et al.. (2017). Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. OncoImmunology. 6(9). e1339856–e1339856. 9 indexed citations
16.
Kaderbhaï, Courèche, Corentin Richard, Jean David Fumet, et al.. (2017). Antibiotic Use Does Not Appear to Influence Response to Nivolumab. Anticancer Research. 37(6). 3195–3200. 96 indexed citations
17.
Kaderbhaï, Courèche, Corentin Richard, Jean David Fumet, et al.. (2017). Response to first-line chemotherapy regimen to predict efficacy of nivolumab in lung cancer.. Journal of Clinical Oncology. 35(15_suppl). 3026–3026. 4 indexed citations
18.
Thévenot, Thierry, Vincent Di Martino, Aurélie Lagrange, et al.. (2006). Granulomatous hepatitis and hemophagocytic syndrome after bacillus Calmette-Guerin bladder instillation. Gastroentérologie Clinique et Biologique. 30(3). 480–482. 8 indexed citations
19.
Mamounas, EP, et al.. (2006). Dose intensity comparison of African-American and white patients in NSABP breast treatment trials of postoperative doxorubicin and cyclophosphamide. Journal of Clinical Oncology. 24(18_suppl). 6111–6111. 1 indexed citations
20.
Mamounas, EP, et al.. (2005). Impact of ethnic neutropenia disparity analysis in NSABP breast trials of postoperative doxorubicin (A)/cyclophosphamide (C). Journal of Clinical Oncology. 23(16_suppl). 6002–6002. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean David Fumet Breakdown of academic impact, for papers by Yinan Dong Breakdown of academic impact, for papers by Rahima Jamal Breakdown of academic impact, for papers by Jichang Han Breakdown of academic impact, for papers by Andrea Castro Breakdown of academic impact, for papers by Marco La Placa Breakdown of academic impact, for papers by François Audhuy Breakdown of academic impact, for papers by Vanesa de Luque Breakdown of academic impact, for papers by Farid Ghorbaninezhad Breakdown of academic impact, for papers by Mei Cao
Rankless by CCL
2026